Alkermes Stock Forecast for 2023 - 2025 - 2030
Updated on 04/19/2024
Alkermes Stock Forecast and Price Target
If the average price target of $34.00 set by three distinguished experts for Alkermes over the past few weeks is reached this year, there would be a potential upside of approximately 43.1% from the last closing price in April, 2024. This potential increase is based on a high estimate of $50.00 and a low estimate of $23.00. If you are not interested in ALKS stock, you may still be interested in its competitors and their current standings.
43.10% Upside
Alkermes Fair Value Forecast for 2023 - 2025 - 2030
Alkermes's Price has decreased In the last four years, from $12.86 to $0.00 – a 100.00% drop. For next year, analysts predict Fair Value of $63.41, which would mean an increase of 100.00%. Over the next seven years, experts predict that Alkermes's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$745.95 | Buy/Sell | $636.99 | 12.27% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$145.74 | Buy/Sell | $174.55 | 16.65% |
| MRK Stock Forecast | Merck | Outperform |
2
|
$125.23 | Buy/Sell | $130.51 | 11.00% |
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$164.66 | Buy/Sell | $178.42 | 14.78% |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
17
|
£109.14 | Buy/Sell | £165.99 | 48.27% |
Alkermes Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Alkermes's Revenue has grown by 60.13%, rising from $1.04B to $1.66B. In the following year, 10 experts forecast Alkermes's Revenue will decrease by 9.63%, to $1.50B. Over the next seven years, experts predict that Alkermes's Revenue will grow at a rate of 6.67%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$25.39 | Buy/Sell | $32.87 | 20.13% |
| SAN Stock Forecast | Sanofi | Outperform |
16
|
85.23€ | Buy/Sell | 102.80€ | 26.72% |
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$48.30 | Buy/Sell | $58.15 | 13.87% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| RKT Stock Forecast | Reckitt Benckiser Group | Outperform |
12
|
£41.39 | Buy/Sell | £66.68 | 38.92% |
| TEVA Stock Forecast | Teva Pharmaceutical Industries | Outperform |
12
|
$12.78 | Buy/Sell | $11.59 | 25.20% |
| VTRS Stock Forecast | Viatris Inc | Hold |
8
|
$11.12 | Buy/Sell | $11.73 | 7.91% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 500257 Stock Forecast | Lupin | Hold |
12
|
Rp1.59k | Buy/Sell | Rp1.11k | -2.74% |
| JAZZ Stock Forecast | Jazz Pharmaceuticals | Outperform |
14
|
$109.27 | Buy/Sell | $188.32 | 73.88% |
| ITCI Stock Forecast | Intra-Cellular Therapies | Outperform |
10
|
$72.00 | Buy/Sell | $79.10 | 15.97% |
Alkermes EBITDA Forecast for 2023 - 2025 - 2030
Alkermes's EBITDA has seen impressive growth In the last three years, rising from $-30.57M to $489.30M – a growth of 1700.59%. According to 4 analysts, Alkermes's EBITDA will fall by 13.67% in the next year, reaching $422.40M. For the next seven years, the forecast is for EBITDA to grow by 34.27%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| HLUN A Stock Forecast | H. Lundbeck A/S | Outperform |
18
|
kr32.54 | Buy/Sell | kr190.00 | 12.17% |
| INSM Stock Forecast | Insmed | Buy |
11
|
$24.80 | Buy/Sell | $41.42 | 69.35% |
| TGTX Stock Forecast | TG Therapeutics | Outperform |
9
|
$13.99 | Buy/Sell | $29.44 | 143.03% |
Alkermes EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Alkermes's EBIT has grown by 468.34%, rising from $-112.43M to $414.12M. In the following year, 8 experts forecast that Alkermes's EBIT will decrease by 29.35%, to $292.58M. Over the next seven years, experts believe that Alkermes's EBIT will grow at a rate of 25.70%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| INDV Stock Forecast | Indivior PLC | Buy |
14
|
£15.24 | Buy/Sell | £28.89 | 106.69% |
| SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$28.87 | Buy/Sell | $41.00 | 38.55% |
| COPN Stock Forecast | Cosmo Pharmaceuticals N.V. | Buy |
12
|
CHF71.20 | Buy/Sell | CHF76.55 | 32.12% |
Alkermes EPS Price Prediction Forecast for 2023 - 2025 - 2030
Alkermes's EPS has decreased In the last four years, from $0.43 to $0.00 – a 100.00% drop. For next year, analysts predict EPS of $2.12, which would mean an increase of 100.00%. Over the next seven years, experts predict that Alkermes's EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BDSI Stock Forecast | BioDelivery Sciences Internati... | - |
11
|
$5.59 | Buy/Sell | $10.00 | 16.46% |
| VNDA Stock Forecast | Vanda Pharmaceuticals | Hold |
0
|
$4.97 | Buy/Sell | $4.25 | -100.00% |
| ORX Stock Forecast | Orexo AB (publ) |
6
|
kr17.20 | Buy/Sell | kr25.50 | 30.81% |
.jpg)